Ghent University Academic Bibliography

Journal Article
A1
open access

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

Franco Maggiolo, Giuliano Rizzardini, Jean‐Michel Molina, Federico Pulido, Stephane De Wit, Linos Vandekerckhove (UGent) , Juan Berenguer, Michelle L. D'Antoni, Christiana Blair, Susan K. Chuck, et al.

(2023) HIV MEDICINE. 24(1). p.27-36

Add to list

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium

Rakan Nasreddine, Eric Florence, Jean Cyr Yombi, Sophie Henrard, Gilles Darcis, Jens Van Praet (UGent) , Linos Vandekerckhove (UGent) , Sabine D. Allard, Rémy Demeester, Peter Messiaen, et al.

(2023) HIV MEDICINE. 24(8). p.914-924

Add to list

HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

Sarah Amele, Anastasia Karachalia Sandri, Alison Rodger, Linos Vandekerckhove (UGent) , Thomas Benfield, Ana Milinkovic, Claudine Duvivier, Hans-Jurgen Stellbrink, Helen Sambatakou, Nikoloz Chkhartishvili, et al.

(2022) HIV MEDICINE. 23(6). p.684-692

Add to list

Mortality under early access to antiretroviral therapy vs Eswatini’s national standard of care : the MaxART clustered randomized stepped‐wedge trial

A Chao, D Spiegelman, S Khan, F Walsh, S Mazibuko, M Pasipamire, B Chai, R Reis, K Mlambo, Wim Delva (UGent) , et al.

(2020) HIV MEDICINE. 21(7). p.429-440

Add to list

Journal Article
A1
open access

Incidence rate, predictors and outcomes of interruption of HIV care : nationwide results from the Belgian HIV cohort

D. Van Beckhoven, E. Florence, S. De Wit, C. Wyndham-Thomas, A. Sasse, Herman Van Oyen (UGent) and J. Macq

(2020) HIV MEDICINE. 21(9). p.557-566

Add to list

Journal Article
A1
open access

Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy

Ingeborg E.A. Wijting, Sofie Rutsaert (UGent) , Casper Rokx, David M. Burger, Annelies Verbon, Jeroen J. A. van Kampen, Charles A. B. Boucher, Bart J. A. Rijnders and Linos Vandekerckhove (UGent)

(2019) HIV MEDICINE. 20(1). p.63-68

Add to list

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

S. Amele, L. Peters, M. Sluzhynska, A. Yakovlev, A. Scherrer, P. Domingo, J. Gerstoft, J. P. Viard, M. Gisinger, R. Flisiak, et al.

(2019) HIV MEDICINE. 20(4). p.264-273

Add to list

Monitoring PrEP implementation in Belgium : national surveillance results, 2017-2018

J. Deblonde, D. Van Beckhoven, E. Florence, A. Libois, Steven Callens (UGent) , S. Henrard, M. Moutchen, S. D. Allard, P. Messiaen, P. De Munter, et al.

(2019) HIV MEDICINE. 20(S9). p.33-34

Add to list

Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

A Roen, K Laut, A Pelchen-Matthews, E Borodulina, L Caldeira, A Clarke, B Clotet, A d'Arminio Monforte, G Fätkenheuer, JM Gatell Artigas, et al.

(2018) HIV MEDICINE. 19(4). p.252-260

Add to list

Journal Article
A1
open access

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

A Cozzi-Lepri, R Zangerle, L Machala, K Zilmer, M Ristola, C Pradier, O Kirk, H Sambatakou, G Faetkenheuer, I Yust, et al.

(2018) HIV MEDICINE. 19(2). p.102-117

Academic Bibliography

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium

HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

Mortality under early access to antiretroviral therapy vs Eswatini’s national standard of care : the MaxART clustered randomized stepped‐wedge trial

Incidence rate, predictors and outcomes of interruption of HIV care : nationwide results from the Belgian HIV cohort

Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

Monitoring PrEP implementation in Belgium : national surveillance results, 2017-2018

Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

Contents

Support

Contact